Home > Healthcare > Medical Devices > Diagnostic Devices > PARP Inhibitor Biomarkers Market

PARP Inhibitor Biomarkers Market Share

Report ID: GMI9191
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

PARP Inhibitor Biomarkers Market Share

The PARP inhibitor biomarkers sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command significant influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

PARP Inhibitor Biomarkers Market Companies

Some of the eminent market participants operating in the PARP inhibitor biomarkers industry include:

Agilent Technologies, Inc.
Ambry Genetics
Amoy Diagnostics Co., Ltd.
Centogene N.V
Illumina, Inc.
Invitae Corporation
Myriad Genetics, Inc.
Neogenomics, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market size for PARP inhibitor biomarkers was USD 905.3 million in 2023 and is expected to register 8.3% CAGR from 2024-2032 owing to the increasing prevalence of cancer and growing demand for personalized mediations worldwide.

PARP inhibitor biomarkers industry from the kits segment is expected to record USD 1.1 million by 2032 due to increasing prevalence of cancer, particularly breast and ovarian cancers, heightening the demand for effective treatment options such as PARP inhibitors.

North America industry reached USD 369.4 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to growing occurrence of cancer in the region, particularly breast and ovarian cancers, which are key focuses for PARP inhibitors.

Agilent Technologies, Inc., Ambry Genetics, Amoy Diagnostics Co., Ltd., Centogene N.V, Illumina, Inc., Invitae Corporation, Myriad Genetics, Inc., Neogenomics, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc., are some of the major PARP inhibitor biomarkers companies worldwide.